Results 111 to 120 of about 4,828 (174)

The impact of nirsevimab prophylaxis on RSV hospitalizations: a real-world cost-benefit analysis in Tuscany, Italy. [PDF]

Front Public Health
Lastrucci V, Pacifici M, Alderotti G, Puglia M, Berti E, Barbati F, Lodi L, Boscia S, Nieddu F, Indolfi G, Peroni D, Martini M, Azzari C, Voller F, Moriondo M, Ricci S.   +15 more
europepmc   +1 more source

Nirsevimab for preventing respiratory syncytial virus lower respiratory tract infections in infants: a systematic review and meta-analysis. [PDF]

Front Public Health
Soudani S, Bertizzolo L, Ghemmouri M, Chappell M, McCool R, Reddish K, Miller P, Barker E, Fewster H.   +8 more
europepmc   +1 more source

Cost-Effectiveness and Public Health Impact of Universal Prophylaxis with Nirsevimab Against Respiratory Syncytial Virus (RSV) Infections in all Infants in Japan. [PDF]

Infect Dis Ther
Noto S, Kieffer A, Soudani S, Arashiro T, Tadera C, Eymere S, Lemański T, Wang X.   +7 more
europepmc   +1 more source

A practical guidance on the prevention and treatment of childhood respiratory syncytial virus infection in Kurdistan. [PDF]

Front Pediatr
Haleem AA, Alsaqee A, Dizayi LA, Hanna SL, Rabaty AA, Pedawi S, Salih AF.   +6 more
europepmc   +1 more source

Expert consensus on the burden of respiratory syncytial virus disease and the utility of nirsevimab for disease prevention and protection of infants. [PDF]

World J Pediatr
Goh DYT, Goh A, Chen CK, Chan SM, Khoo PC, Thoon KC, Li J, Lee BW, Yung CF.   +8 more
europepmc   +1 more source

Respiratory Syncytial Virus Infection Triggering a Pulmonary Hypertensive Crisis in a Boy With Prader-Willi Syndrome-Associated Sleep-Disordered Breathing. [PDF]

Cureus
Tsukahara M, Yagasaki H, Makino K, Sano T, Inukai T.   +4 more
europepmc   +1 more source

Prevention of respiratory syncytial virus disease by immunisation. [PDF]

Arch Dis Child Educ Pract Ed
Benzaken TR, Watson C, Drysdale SB.
europepmc   +1 more source

Molecular and Cellular Mechanisms of Respiratory Syncytial Viral Infection: Its Implications for Prophylactic and Therapeutic Pharmaceuticals. [PDF]

MedComm (2020)
Liang X, Yin Y, Lin Y, Chen S, Qian Q, Yuan J, Yang L, Yang Y.   +7 more
europepmc   +1 more source

Adherence to Palivizumab for Respiratory Syncytial Virus Prophylaxis in Romanian Infants. [PDF]

Vaccines (Basel)
Calomfirescu-Avramescu A, Toma AI, Mehedințu C, Năstase L, Dima V.   +4 more
europepmc   +1 more source